Search
Matinas BioPharma Holdings Inc
MTNBAdd to Watchlist
0.665USD
+0.001+0.09%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
3.92MMarket Cap
LossP/E TTM
More Details of Matinas BioPharma Holdings Inc Company
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Matinas BioPharma Holdings Inc Info
Ticker SymbolMTNB
Company nameMatinas BioPharma Holdings Inc
IPO dateJun 03, 2014
CEOJabbour (Jerome D)
Number of employees3
Security typeOrdinary Share
Fiscal year-endJun 03
AddressSuite 302
CityBEDMINSTER
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code07921
Phone19084431860
Websitehttps://www.matinasbiopharma.com/
Ticker SymbolMTNB
IPO dateJun 03, 2014
CEOJabbour (Jerome D)
Company Executives of Matinas BioPharma Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jerome D. Jabbour, J.D.
Mr. Jerome D. Jabbour, J.D.
Chairman of the Board, President, Chief Executive Officer, Director
Chairman of the Board, President, Chief Executive Officer, Director
9.21K
--
Mr. Keith A. Kucinski, CPA
Mr. Keith A. Kucinski, CPA
Chief Financial Officer
Chief Financial Officer
1.89K
--
Ms. Evelyn D'An
Ms. Evelyn D'An
Independent Director
Independent Director
--
--
Dr. Robin L. Smith
Dr. Robin L. Smith
Independent Director
Independent Director
--
--
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Independent Director
Independent Director
--
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jerome D. Jabbour, J.D.
Mr. Jerome D. Jabbour, J.D.
Chairman of the Board, President, Chief Executive Officer, Director
Chairman of the Board, President, Chief Executive Officer, Director
9.21K
--
Mr. Keith A. Kucinski, CPA
Mr. Keith A. Kucinski, CPA
Chief Financial Officer
Chief Financial Officer
1.89K
--
Ms. Evelyn D'An
Ms. Evelyn D'An
Independent Director
Independent Director
--
--
Dr. Robin L. Smith
Dr. Robin L. Smith
Independent Director
Independent Director
--
--
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Independent Director
Independent Director
--
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Matinas BioPharma Holdings Inc?
The top five shareholders of Matinas BioPharma Holdings Inc are: Mr. Jerome D. Jabbour, J.D.
How many institutions hold shares of Matinas BioPharma Holdings Inc (MTNB)?
As of 2026Q1, 81 institutions hold shares of Matinas BioPharma Holdings Inc, with a combined market value of approximately 511.24K, accounting for 7.98% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -956971.00.
